

uncommon, group 1




719G>A, 861L>Q - 2 719G>A - 1 861L>Q - 2 861L>Q - 6 709E>A, 719G>S - 2 719G>C, 768S>I - 1


Time (Months)

uncommon, group 1, subgroups




uncommon, group 1, subgroups continued





exon 20 insertions, group 2



OS afatinib


OS erlotinib


OS gefitinib

OS osimertinib PFS


PFS

PFS





very rare, group 1, subgroups



very rare, group 1, subgroups continued

